Crossing An Ethical Boundary
By Marcy Darnovsky,
The Journal of Life Sciences
| 05. 19. 2008
What prompted the recent headlines about genetically-modified human embryos? Why did a brief account of an experiment at Cornell University, presented last fall at an American Society for Reproductive Medicine conference and then published without fanfare in its journal Fertility and Sterility, suddenly make news around the world?
The work in question involved transferring a gene that codes for a fluorescing protein into a non-viable human embryo, and showing that all the cells in the embryo glowed after three days of cell division. As one of the research team's members later acknowledged, it was the first time that scientists are known to have created a genetically-modified human embryo.
Strangely, the study stayed beneath the public and media radar for months. It was brought to the attention of the UK's Sunday Times by Dr. David King, director of the British organization Human Genetics Alert, who came across it recently while reading a document prepared by the Human Fertilization and Embryology Authority. The story ran in the May 11 Sunday Times and was then picked up by the Associated Press and...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...